Skip Navigation LinksHome   >   Our Pipeline   >   Programme 2 OCT130401

Programme 2 – OCT130401: Drug/Device Combination

  • Pre-clinical development underway, initially targeting trigeminal neuralgia
  • Aim to begin Phase 1 in Q4 2022
  • Orphan indication market exclusivity 7 yrs US and 10 yrs EU/JP
  • Advanced by OzUK and Purysis

Trigeminal Neuralgia 

Trigeminal Neuralgia (TN) is a severe type of face pain.  This condition causes debilitating and excruciating pain, has a fast and unexpected onset and because of this has been difficult to treat. Sufferers experience an intense, stabbing electric shock-like pain. Each episode may only last few seconds or minutes, but some people will suffer multiple (up to 100) episodes in one day.[i]   Our medicine will be designated orphan status and delivered via an inhaler which may mean faster onset of pain relief when compared to other routes.[ii]. Cases are increasing with between approximately 10,000 and 15,000 new cases in the United States diagnosed each year.[iii] The Directors estimate that in 2021 there were more than 77,000 people living with the condition in the UK.[iv]